The IMG-7289-CTP-201 study is a Phase 2 study in patients with a diagnosis of ET. To enter this study, patients must have a platelet count above the normal range in need of treatment. Patients must also have been treated with another platelet-lowering drug that no longer benefits them.
Participants will need to visit a study site to see if they meet the criteria for the study.
The initial treatment period with bomedemstat is 24 weeks (about 6 months), during which, participants will visit the clinic about 10 times. There will be regular physical examinations and laboratory tests such as blood counts. In addition, there will be bone marrow samples taken before the start of treatment and at Week 24.
Participants receiving clinical benefit from bomedemstat can continue treatment beyond 24 weeks.